RIBOVIZ
How to optimize the delivery of siRNA to treat liver diseases
Project description
This project involves the optimization of a crystallography process of the eukaryotic ribosome, alone or in combination with ligands.
This invention based on the crystallization of the eukaryotic ribosome is unique in the world. This research tool offers the possibility to design and optimize molecules to fight infectious diseases such as fungi and parasites.
In the longer term, this process could make it possible to develop human ribosome modulators to treat rare diseases or cancer.
Why does Conectus invest in this project?
Conectus' financial investment will improve the performance of this tool and its resolution.
At the origin of the project:
Nicolas Garreau de Loubresse of the Institute of Genetics and Molecular and Cellular Biology
Focus
Conectus is investing in this project: 162 268 €.
Duration: 18 months